[2025] BREDIS Healthcare Attends the International Conference of the Korean Dementia Association (IC-KDA & ASAD 2025)

On May 8, 2025, BREDIS Healthcare participated in the International Conference of the Korean Dementia Association (IC-KDA & ASAD 2025), held at Lotte Hotel World in Seoul. The conference featured active discussion on the latest research trends in the diagnosis and treatment of Alzheimer's disease, including early diagnosis strategies based on blood biomarkers and the clinical application of disease-modifying therapies. BREDIS Healthcare presented two poster sessions at the conference, sharing its research findings. The first study, "Drivers of Dementia Prevention Technology Adoption in Cognitively Healthy Adults," analyzed the factors influencing the adoption of dementia prevention technologies among cognitively healthy adults. Using a framework that integrates protection motivation theory with the technology acceptance model, the study found that risk perception and self-efficacy are key drivers of adoption for complementary health information systems such as blood biomarker analysis. The second study, "Optimizing Clinical Utilization of Blood Biomarker Analysis Results Using Bayesian Hidden Markov Models," proposed an analytical framework based on Bayesian hidden Markov models to improve the clinical utility of blood biomarkers in diagnosing Alzheimer's disease. Using pTau217 measured via SIMOA HD-X as the core biomarker and integrating demographic and neurocognitive data, the framework reduced the rate of indeterminate diagnoses by more than 50% compared to single-biomarker measurement, while maintaining equivalent sensitivity and specificity. Going beyond simply introducing its solutions, BREDIS Healthcare presented its own research findings directly, continuing to make a substantive contribution to advances in the early diagnosis of Alzheimer's disease.